ClinicalTrials.gg
CompletedNCT07854418Updated Oct 2, 2026

The Efficacy and Safety of Winona Barrier Special Cream in Post-acne Erythema a Parallel Randomized Controlled Study

An observational study in Acne Vulgaris, sponsored by The First Affiliated Hospital with Nanjing Medical University. Completed at 1 site in China. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Observational

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
80
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 35 studies in Acne Vulgaris with a site in China — 8 open to participants now, 10 under way, 2 of them phase 3. Acne Vulgaris · China.

Started
2023
the only one that year
Observational
2 of 35
none open now
Registered
35th of 35
by date

Among the 35 studies in Acne Vulgaris with a site in China, this one is the only one that started in 2023, is one of 2 observational ones, and was the 35th registered.

Acne Vulgaris

795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

8 of the 35 studies in Acne Vulgaris with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 48 Acne Vulgaris studies recruiting now, 17 (35%) set no upper age limit and 30 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Acne Vulgaris with a site in China, or all of them as a file.
02

Study summary

The goal of this study is to evaluate the efficacy and safety of winona barrier special cream in post-acne erythema(PAE). The main questions it aims to answer are: whether winona barrier special cream can improve facial skin erythema, transepidermal water loss, water content of stratum corneum, pH,melanin, lipidomic and microbiodemic in patients with PAE .

type of study:clinical trial participant population/health conditions The study proposes to recruit 60 PAE patients and 20 healthy individuals The checks of patients were randomly selected to use winona barrier special cream on one side and the Basal Water on the other side. the sampes of surface skin are collected on week0, week4 and week8. Measurements of erythema, transepidermal water loss, stratum corneum water content, pH, and melanin were taken from fixed lesion sites on both cheeks before on week0, week4 and week8.

Researchers will compare differences in facial lipidomics and microbiomics between patients' lesion sites and the healthy population, as well as before and after the use of creams by patients to see whether the lipidomics and microbiomics at skin lesions are different in PAE patients compared to the healthy population and whether the intensive care cream has an improved effect on them.

Read the detailed description

This trial is a single-center, randomized controlled study. Eighty subjects are to be recruited. Subjects are divided into a healthy control group (20 people, healthy people without PAE and other inflammatory skin diseases on the face) and a test group (60 people, patients who meet the diagnostic criteria for PAE). Subjects avoided strenuous exercise and sweating for 3 hours before the test, and avoided the use of sunscreen, foundation and other cosmetics. The temperature of the test environment was controlled at 20-25°C and humidity at 45-50%.

At the time of enrollment, patients were informed of the precautions to be taken and signed an informed consent form. The healthy control group used CK sebaceous tape to adhere a 1-cm skin sample from the lateral side of the cheeks and nose at the level of both cheeks and noses for multi-histological testing (sebum, microbiology, and other histological analyses) in order to compare the facial histological differences between the healthy individuals and the patients with PAE.

The test group was 60 people, using the left and right half of the face in an auto-control manner, randomly selected to use the Winona Barrier Multi-Repair Cream on one cheek and the Base Cream on the other. One erythematous area on each cheek was selected at the time of enrollment, and skin elasticity was measured using Cutometer® Dual MPA580 (Courage+Khazaka, Germany), stratum corneum water content was measured using Corneometer CM825 (Courage+Khazaka, Germany), and water content of the stratum corneum was measured using Sebumeter® SM815 (Courage+Khazaka, Germany) for sebum content, Tewameter® (Courage+Khazaka, Germany) for transepidermal water loss (TEWL) and pH-Meter PH905 (Courage+Khazaka, Germany) for pH, Mexameter® MX18 (Courage+Khazaka, Germany) for melanin and erythema; L*, a*, b* values were measured with an L*a*b* colorimeter (Konica-Minolta, Japan); and skin samples were adhered to a CK sebaceous tape (Courage+Khazaka, Germany) for a multihistological test. (sebum, microorganisms, etc.); VISIA® (Canfield, USA) skin image analyzer was used to collect frontal, left and right photographs of the patient's face. The patients were followed up at weeks 4 and 8 to record any adverse reactions, and the above skin physiological parameters and dermatologic sampling were performed in the same erythematous area. Frontal, left and right photographs of the patient's face at the end of treatment were taken at week 8 using the VISIA® Skin Image Analyzer.

The efficacy of the treatment was assessed by comparing the differences between the treated and non-treated erythema, skin test indices, and histologic findings in control patients. The safety of the treatment was assessed by the presence or absence of adverse effects. The effect of treatment on skin metabolomics was also assessed by comparing skin metabolomic differences between PAE patients before and after treatment and with normal subjects.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Between March 2023 to May 2023, patients diagnosed with post-acne erythema and meeting the inclusion criteria were enrolled in the study from the Department of Dermatology at Jiangsu Provincial People's Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. adults between 18 and 40 years old, regardless of gender;
  2. comply the clinical diagnostic criteria for post-acne erythema;
  3. patients understand and are willing to participate in this clinical trial and voluntarily sign an form;

Exclusion criteria

Exclusion Criteria:

  1. patients with facial comorbidities such as atopic dermatitis, rosacea, seborrheic dermatitis, and other facial skin diseases that may affect the evaluation of efficacy;
  2. those who have been treated with topical acne or other skin disease medications on the face within 1 month;
  3. those who have taken oral antibiotics, isotretinoin and other acne systemic treatment drugs within one month;
  4. Those who have laser, intense pulse light, radio frequency, high-energy focused ultrasound and other photoelectric treatments within one month;
  5. Those who are using , antihistamines and antibiotics or efficacious skin care products in the week before enrollment;
  6. Those who have a history of allergy to the skin care products and ingredients used this time;
  7. Those with serious heart, brain, lung, liver and kidney function damage;
  8. Pregnant and lactating women;
  9. Those who have a history of psychological and mental illness, recent history of alcoholism or drug abuse;
  10. patients who are unwilling to sign the and who are unwilling to cooperate.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
80 participants (actual)
Target follow-up
8 Days
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • PAE patients

    the patients

    Other: Treatment and control groups

Interventions

  • OtherTreatment and control groups

    The checks of patients were randomly selected to use winona barrier special cream on one side and the Basal Water on the other side. the sampes of surface skin are collected on week0, week4 and week8. Measurements of erythema, transepidermal water loss, stratum corneum water content, pH, and melanin were taken from fixed lesion sites on both cheeks before on week0, week4 and week8.

06

What researchers measure

Primary outcomes

  1. Global Aesthetic Improvement Scale (GAIS) score

    The overall aesthetic improvement of facial skin will be assessed by a blinded evaluator using the Global Aesthetic Improvement Scale (GAIS). The GAIS score will be assigned to each side of the face according to the following criteria: -1 = worsened; 0 = no improvement; 1 = slight improvement; 2 = marked improvement; 3 = near complete recovery. The assessment will be performed at 3 days and 7 days after treatment.

    Time frame: 3 days (T3d) and 7 days (T7d) after treatment

Secondary outcomes

  1. Transepidermal water loss (TEWL)

    Transepidermal water loss (TEWL) will be measured using the GPSkin Barrier skin physiological measurement device (GPOWER, Republic of Korea). Measurements will be obtained at the predefined facial cheek site, located at the intersection of the vertical line through the center of the eye and the horizontal line through the center of the nasal bridge. TEWL will be recorded in g/(m²·h).

    Time frame: Baseline (BL), immediately after treatment (Timm), 2 hours after treatment (T2h), 3 days after treatment (T3d), and 7 days after treatment (T7d)

  2. Stratum corneum hydration (SCH)

    Measurements will be obtained at the predefined facial cheek site, located at the intersection of the vertical line through the center of the eye and the horizontal line through the center of the nasal bridge.

    Time frame: Baseline (BL), immediately after treatment (Timm), 2 hours after treatment (T2h), 3 days after treatment (T3d), and 7 days after treatment (T7d)

  3. CIELAB a* value measured by colorimetry

    The CIELAB a\* value of facial skin will be measured using a CM-700d spectrophotometer (Konica Minolta, Japan). Measurements will be obtained at the predefined facial cheek site, located at the intersection of the vertical line through the center of the eye and the horizontal line through the center of the nasal tip.

    Time frame: Baseline (BL), immediately after treatment (Timm), 2 hours after treatment (T2h), 3 days after treatment (T3d), and 7 days after treatment (T7d)

  4. Facial red area percentage assessed by VISIA imaging

    Standardized facial images will be acquired using the VISIA facial imaging system (Canfield Scientific, USA), with imaging of the left, central, and right cheek regions. The percentage of facial red area will be quantitatively analyzed from the acquired images using Image-Pro Plus (IPP) software.

    Time frame: Baseline (BL) and 7 days after treatment (T7d)

07

Study locations

1 site
  • Jiangsu Province Hospital, the First Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in Jul 2023, 3 months.

Of 38 observational studies under Acne Vulgaris, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2026
First posted
Oct 2, 2026
StartActual
Apr 1, 2023
Primary completionActual
Jul 30, 2023
CompletionActual
Jul 30, 2023
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07854418
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Apr 1, 2023
Primary completion
Jul 30, 2023
Completion
Jul 30, 2023
Last update
Oct 2, 2026

Study contacts

Yang Xu
principal investigator · The First Affiliated Hospital with Nanjing Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion